These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 10168037)

  • 1. Cost utility in second-line metastatic breast cancer.
    Berdeaux G; Hurteloup P
    Pharmacoeconomics; 1997 May; 11(5):492-7. PubMed ID: 10168037
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost effectiveness of treatment options in advanced breast cancer in the UK.
    Brown RE; Hutton J; Burrell A
    Pharmacoeconomics; 2001; 19(11):1091-102. PubMed ID: 11735676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer.
    Leung PP; Tannock IF; Oza AM; Puodziunas A; Dranitsaris G
    J Clin Oncol; 1999 Oct; 17(10):3082-90. PubMed ID: 10506603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cost-utility analysis of second-line chemotherapy in metastatic breast cancer. Docetaxel versus paclitaxel versus vinorelbine.
    Launois R; Reboul-Marty J; Henry B; Bonneterre J
    Pharmacoeconomics; 1996 Nov; 10(5):504-21. PubMed ID: 10169397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A medico-economic evaluation of second line chemotherapy in metastatic breast cancer: comparison between docetaxel, paclitaxel, and vinorelbine].
    Launois RJ; Reboul-Marty JM; Bonneterre J
    Bull Cancer; 1997 Jul; 84(7):709-21. PubMed ID: 9339197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel and docetaxel. Innovation, but at what cost?
    Lønning PE
    Pharmacoeconomics; 1995 Jul; 8(1):1-4. PubMed ID: 10155597
    [No Abstract]   [Full Text] [Related]  

  • 7. A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer.
    Lister-Sharp D; McDonagh MS; Khan KS; Kleijnen J
    Health Technol Assess; 2000; 4(17):1-113. PubMed ID: 11074389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docetaxel. A pharmacoeconomic review of its use in the treatment of metastatic breast cancer.
    Lamb HM; Wiseman LR
    Pharmacoeconomics; 1998 Oct; 14(4):447-59. PubMed ID: 10344911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Recent results of anticancer drugs acting on microtubules--navelbine, taxol and taxotere for the treatment of lung cancer].
    Kawahara M; Furuse K
    Gan To Kagaku Ryoho; 1992 Nov; 19(13):2150-6. PubMed ID: 1359840
    [No Abstract]   [Full Text] [Related]  

  • 10. Introduction: taxoids and the management of breast cancer.
    Hortobagyi GN
    Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-1-S13-2. PubMed ID: 9335510
    [No Abstract]   [Full Text] [Related]  

  • 11. [Treatment outcomes with vinorelbine for metastatic breast cancer patients previously treated with both doxorubicin and docetaxel].
    Tashiro H; Sonoda K; Ohshiro T; Ohta M; Yamamura S; Ishikawa T; Itasaka H; Matsusaka T; Kume K
    Gan To Kagaku Ryoho; 2001 Oct; 28(10):1397-401. PubMed ID: 11681247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress in preclinical and clinical studies for the development of new anticancer drugs in Japan, with emphasis on taxanes.
    Saijo N; Nishio K; Ohta S; Arioka H; Funayama Y; Fukuoka K; Kurokawa H; Nomoto T; Ishida T; Yamamoto N; Tamura T; Shinkai T; Eguchi K; Ohe Y; Kunito H; Ohtsu T; Sasaki Y
    Cancer Chemother Pharmacol; 1996; 38 Suppl():S11-5. PubMed ID: 8765409
    [No Abstract]   [Full Text] [Related]  

  • 13. [From conquering metastatic disease to adjuvant therapy: clinical evolution of docetaxel in breast cancer].
    Cartenì G
    Tumori; 2001; 87(6):A1-5. PubMed ID: 11995695
    [No Abstract]   [Full Text] [Related]  

  • 14. The role of taxanes in the management of breast cancer.
    Nabholtz JM
    Semin Oncol; 1999 Jun; 26(3 Suppl 8):1-3. PubMed ID: 10403466
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients.
    Brown RE; Hutton J
    Anticancer Drugs; 1998 Nov; 9(10):899-907. PubMed ID: 9890701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docetaxel (Taxotere) for advanced breast cancer.
    Med Lett Drugs Ther; 1996 Sep; 38(984):87-8. PubMed ID: 8828520
    [No Abstract]   [Full Text] [Related]  

  • 17. Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer.
    Ibrahim NK; Sahin AA; Dubrow RA; Lynch PM; Boehnke-Michaud L; Valero V; Buzdar AU; Hortobagyi GN
    Lancet; 2000 Jan; 355(9200):281-3. PubMed ID: 10675076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Vinorelbine in the treatment of non-small-cell lung cancer and breast cancer].
    Kubota K
    Gan To Kagaku Ryoho; 2000 Jul; 27(8):1301-6. PubMed ID: 10945030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel and docetaxel in breast and ovarian cancer.
    Drug Ther Bull; 1997 Jun; 35(6):43-6. PubMed ID: 9282422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docetaxel in anthracycline-resistant metastatic breast cancer.
    Hui YF; Ignoffo RJ
    Cancer Pract; 1997; 5(2):124-7. PubMed ID: 9110651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.